Loxo Oncology, an early-stage biotech developing targeted therapies to treat solid tumors, raised $68 million by offering 5.3 million shares (vs. 4.4 million originally planned) at $13, the midpoint of the $12 to $14 range. Loxo Oncology will list on the NASDAQ under the symbol LOXO. Cowen & Company and Stifel acted as joint bookrunners on the deal.
